A detailed history of Johnson Financial Group, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Johnson Financial Group, Inc. holds 10 shares of NBIX stock, worth $1,253. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10
Holding current value
$1,253
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $1,308 - $1,431
10 New
10 $1,000
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $10,432 - $13,652
-144 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $11,469 - $15,295
144 New
144 $12,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Johnson Financial Group, Inc. Portfolio

Follow Johnson Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Johnson Financial Group, Inc. with notifications on news.